Healthcare Industry News: glioblastoma multiforme
News Release - October 3, 2007
Bradmer Announces Management ChangesTORONTO, Oct. 3 (HSMN NewsFeed) - Bradmer Pharmaceuticals Inc., a biopharmaceutical company dedicated to the development and commercialization of cancer therapies, today announced that it has appointed Zafeer Ahmad, Ph.D, to the position of Vice President, Manufacturing Operations, and that it has accepted the resignation of Kerry M. Barnhart, Ph.D, as President and Chief Scientific Officer effective November 1, 2007. Chief Executive Officer Alan M. Ezrin, Ph.D. will assume the additional role of President.
"Dr. Ahmad brings a wealth of knowledge in late-stage drug development. As we prepare to submit our proposed multi-center Phase III trial protocol and manufacturing data for Neuradiab to the FDA, Dr. Ahmad's experience in working with contract research and contract manufacturing organizations will be indispensable to Bradmer. Zafeer will also be a strong addition to our team as we complete the validation and transfer of drug production from Duke University to a commercial manufacturer," said Dr. Ezrin, Chief Executive Officer of Bradmer. "Dr. Barnhart made a significant contribution to Bradmer at an early stage and we wish him our best as he pursues other opportunities. His decision to leave at this stage, after we've recruited a team with broad experience in preparation for initiating the Phase III trial, will allow us to make a seamless transition in the roles and responsibilities of the existing management team."
Dr. Ahmad most recently held the position of Vice President, Process Development and Manufacturing at NeoPharm, Inc. Prior to his work with NeoPharm, Dr. Ahmad held senior positions at GlaxoSmithKline plc and Hoffmann-La Roche Inc. He has more than 19 years of industry experience in drug development, aseptic manufacturing operations, facility design and validation, batch record and SOP preparation, outsourcing, tech transfer, process validation and regulatory submission of drugs. Based on this experience, Dr. Ahmad has a strong working knowledge of cGMP and CMC documentation for IND and BLA preparation. From an academic perspective, Dr. Ahmad held the position of Senior Scientist/Assistant Professor at Indiana University, and was a Visiting Fellow at the National Institutes of Health in Bethesda, MD. He received his Ph.D in Biochemistry from Aligarh University in India. He has published numerous peer reviewed articles including nine papers in the Journal of Biological Chemistry.
About Bradmer Pharmaceuticals Inc. (www.bradmerpharma.com)
Bradmer Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of new and innovative cancer therapies. Bradmer's lead clinical candidate, Neuradiab, was developed at Duke University Medical Center as a proprietary therapy for a particularly aggressive form of brain cancer, glioblastoma multiforme. To date, over US$60 million in grants and related support has driven research and development of the licensed treatment, which has been delivered to over 200 patients with promising results and has completed Phase II clinical trials at Duke University. Bradmer is currently in the process of organizing a prospective multi-center clinical trial of the licensed treatment. Neuradiab has been granted Orphan Drug Status by both the U.S. Food and Drug Administration and the European Medicines Agency.
Bradmer Pharmaceuticals Inc.'s common shares have not been registered under the Securities Act of 1933, as amended (the "Securities Act") or any state regulatory agency in the United States. The resale or transfer by a U.S. investor of such common shares of Bradmer Pharmaceuticals Inc. is subject to the requirements of Rule 904 of Regulation S of the Securities Act or such other applicable exemption thereunder, and other applicable state securities laws.
Except for historical information, this press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risk and uncertainties, which may cause but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting.
Source: Bradmer Pharmaceuticals
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.